vTv Therapeutics (VTVT) Total Non-Current Liabilities (2014 - 2022)

vTv Therapeutics has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $13.1 million for Q1 2022.

• Total Non-Current Liabilities for Q1 2022 came in at $13.1 million, up 27.19% year-over-year; the trailing twelve-month figure through Mar 2022 was $13.1 million (up 27.19% YoY), and the FY2021 annual result was $9.0 million, down 17.87% from the prior year.
• Total Non-Current Liabilities came in at $13.1 million for Q1 2022 at vTv Therapeutics, up from $9.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $43.2 million in Q2 2018 to a low of $8.3 million in Q3 2021.
• The 5-year median for Total Non-Current Liabilities is $16.8 million (2020), against an average of $19.9 million.
• Across the five-year window, Total Non-Current Liabilities soared 44.95% in 2018 and slumped 49.82% in 2019, its largest moves.
• vTv Therapeutics' Total Non-Current Liabilities stood at $28.7 million in 2018, then tumbled by 37.75% to $17.8 million in 2019, then plunged by 38.66% to $10.9 million in 2020, then slipped by 17.87% to $9.0 million in 2021, then surged by 46.17% to $13.1 million in 2022.
• The last three Total Non-Current Liabilities figures came in at $13.1 million (Q1 2022), $9.0 million (Q4 2021), and $8.3 million (Q3 2021), per Business Quant data.